After a yearlong delay, FDA approves EpiPen generics

Not a second too soon.

EpiPen still expensive and critics should go “copulate with themselves,” Mylan chairman thinks

But they, you know, “care about the patient” and stuff.

Epinephrine pill might break the EpiPen scandal and give patients their first valid alternative

A simple solution to bypass all the red tape and get where it’s needed — patients.

Mylan CEO Heather Bresch’s hearing on EpiPen was a complete disaster for the company

Congress was not happy with Bresch’s or the FDA’s answers.